Living Cell Technologies (LCT), a biotech company headquartered in Australia, has retracted a 2011 paper purporting to show that their product reversed Parkinson’s symptoms in rats after “being unable to reconfirm their reported results and a possible deviation from the protocol.”
LCT is developing NTCELL, which, according to their site: Continue reading Biotech company retracts Parkinson’s treatment study after “possible deviation from protocol”